Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART
暂无分享,去创建一个
A. Lazzarin | O. Picconi | C. Mussini | A. Scoglio | F. Mazzotta | G. di Perri | S. Bellino | B. Ensoli | A. Tripiciano | F. Ensoli | E. Garaci | C. Torti | G. Carosi | M. Galli | G. Angarano | A. Cafaro | G. Tambussi | S. Marcotullio | S. Rusconi | R. Visintini | R. Espósito | A. Latini | G. Palamara | S. Bonora | L. Sighinolfi | N. Ladisa | O. Longo | V. Francavilla | G. Paniccia | V. Mercurio | C. Ariola | F. Ghinelli | F. Soscia | Donato Scaramuzzi | M. J. Ruiz Alvarez | M. Campagna | M. D. Di Pietro | Angela Arancio | C. Iori
[1] P. Palma,et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children , 2010, AIDS.
[2] J. Li,et al. Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection , 2010, AIDS.
[3] C. Van Lint,et al. HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals , 2010, Science.
[4] P. Volberding,et al. Antiretroviral therapy and management of HIV infection , 2010, The Lancet.
[5] F. Chiodi,et al. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. , 2010, The Lancet. Infectious diseases.
[6] D. O’Connor,et al. Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P , 2010, Journal of Virology.
[7] S. Arold,et al. Phosphatidylinositol‐(4,5)‐bisphosphate enables efficient secretion of HIV‐1 Tat by infected T‐cells , 2010, The EMBO journal.
[8] James Riddell,et al. HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs , 2010, Nature Medicine.
[9] B. Berkhout,et al. Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome , 2009, PloS one.
[10] G. D'offizi,et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. , 2009, Vaccine.
[11] M. Giacca,et al. Immobilized HIV‐1 Tat protein promotes gene transfer via a transactivation‐independent mechanism which requires binding of Tat to viral particles , 2009, The journal of gene medicine.
[12] S. Deeks. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[13] Jiyuan Zhang,et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV‐1‐infected typical progressors, but not in long‐term non‐progressors , 2009, Immunology.
[14] G. D'offizi,et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. , 2009, Reviews on recent clinical trials.
[15] S J Gange,et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.
[16] G. D'offizi,et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. , 2009, Vaccine.
[17] E. Loret,et al. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? , 2009, Retrovirology.
[18] M. A. Curotto de Lafaille,et al. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? , 2009, Immunity.
[19] P. Palma,et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children , 2009, Proceedings of the National Academy of Sciences.
[20] S. Moretti,et al. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). , 2009, Viral immunology.
[21] Jeffrey N. Martin,et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] D. Hazuda,et al. The Challenge of Finding a Cure for HIV Infection , 2009, Science.
[23] M. Magnani,et al. HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection1 , 2009, The Journal of Immunology.
[24] R. Shafer,et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] A. Phillips,et al. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.
[26] P. Narciso,et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.
[27] Yujie Liu,et al. Cellular reservoirs of HIV-1 and their role in viral persistence. , 2008, Current HIV research.
[28] S. Deaglio,et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. , 2008, Physiological reviews.
[29] R. Siliciano,et al. Preservation of FoxP3+ Regulatory T Cells in the Peripheral Blood of Human Immunodeficiency Virus Type 1-Infected Elite Suppressors Correlates with Low CD4+ T-Cell Activation , 2008, Journal of Virology.
[30] J. Altman,et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. , 2008, Immunity.
[31] Dongyang Yu,et al. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. , 2008, Virology.
[32] R. Gavioli,et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. , 2008, Vaccine.
[33] J. Grivel,et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. , 2008, Blood.
[34] V. Appay,et al. Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.
[35] David A. Price,et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.
[36] E. Remmerswaal,et al. A New Subset of Human Naive CD8+ T Cells Defined by Low Expression of IL-7Rα1 , 2007, The Journal of Immunology.
[37] Asier Sáez-Cirión,et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.
[38] M. Magnani,et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. , 2006, AIDS.
[39] K. Nagashima,et al. Proteomic and Biochemical Analysis of Purified Human Immunodeficiency Virus Type 1 Produced from Infected Monocyte-Derived Macrophages , 2006, Journal of Virology.
[40] R. Siliciano,et al. Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells , 2006, PLoS pathogens.
[41] Milton C Weinstein,et al. The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.
[42] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[43] Giulia Marsili,et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. , 2006, The Biochemical journal.
[44] Jeffrey N. Martin,et al. The independent effect of drug resistance on T cell activation in HIV infection , 2006, AIDS.
[45] Jared E. Toettcher,et al. Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.
[46] M. Ciccozzi,et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. , 2005, The Journal of infectious diseases.
[47] B. Ensoli,et al. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. , 2004, Current opinion in biotechnology.
[48] R. Gavioli,et al. Recent advances in the development of HIV-1 Tat-based vaccines. , 2004, Current HIV research.
[49] J. Heeney,et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. , 2004, Vaccine.
[50] Robert F. Siliciano,et al. Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo , 2004, Journal of Virology.
[51] S E Szabo,et al. Evaluation of an automated instrument for viability and concentration measurements of cryopreserved hematopoietic cells. , 2004, Laboratory hematology : official publication of the International Society for Laboratory Hematology.
[52] V. Bond,et al. Extracellular Nef Protein Targets CD4+ T Cells for Apoptosis by Interacting with CXCR4 Surface Receptors , 2004, Journal of Virology.
[53] H. Günthard,et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. , 2004, The Journal of infectious diseases.
[54] M. Colvin,et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. , 2003, The Journal of infectious diseases.
[55] Jianhong Cao,et al. Evolution of CD8+ T Cell Immunity and Viral Escape Following Acute HIV-1 Infection1 , 2003, The Journal of Immunology.
[56] Yuntao Wu,et al. Early Transcription from Nonintegrated DNA in Human Immunodeficiency Virus Infection , 2003, Journal of Virology.
[57] B. Peterlin,et al. Transcriptional Profiles of Latent Human Immunodeficiency Virus in Infected Individuals: Effects of Tat on the Host and Reservoir , 2003, Journal of Virology.
[58] E. Verdin,et al. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.
[59] E. Sandström,et al. HIV subtypes and recombination strains--strategies for induction of immune responses in man. , 2002, Vaccine.
[60] Austin L. Hughes,et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection , 2002, Nature Medicine.
[61] V. Arora,et al. Nef: agent of cell subversion. , 2002, Microbes and infection.
[62] D. Nickle,et al. Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy , 2002, Journal of Virology.
[63] S. Moretti,et al. Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses1 , 2002, The Journal of Immunology.
[64] Yuntao Wu,et al. Selective Transcription and Modulation of Resting T Cell Activity by Preintegrated HIV DNA , 2001, Science.
[65] A. Jordan,et al. The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.
[66] M. Re,et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[67] P. Casanova-Sotolongo,et al. [Association of peripheral facial paralysis in patients with human immunodeficiency virus infection]. , 2001, Revista de neurologia.
[68] M. Giacca,et al. Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans* , 2001, The Journal of Biological Chemistry.
[69] D. Speiser,et al. Human CD8+ T cells expressing HLA‐DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells , 2001, European journal of immunology.
[70] John F. B. Mitchell,et al. Quantifying the uncertainty in forecasts of anthropogenic climate change , 2000, Nature.
[71] Alessandro Sette,et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.
[72] A. Borsetti,et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine , 2000, Journal of medical primatology.
[73] P. Chandra,et al. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties. , 2000, Anticancer Research.
[74] O. Lambotte,et al. Detection of Infectious HIV in Circulating Monocytes From Patients on Prolonged Highly Active Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.
[75] U. Dianzani,et al. Effects of the human CD38 glycoprotein on the early stages of the HIV‐1 replication cycle , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[76] D. Soll,et al. HIV-induced T-cell syncytia release a two component T-helper cell chemoattractant composed of Nef and Tat. , 1999, Journal of cell science.
[77] A. Nel,et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. , 1999, Journal of immunology.
[78] H. Pfister,et al. HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. , 1999, Journal of immunology.
[79] G. Barillari,et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. , 1999, Blood.
[80] A. Osterhaus,et al. Vaccination with Rev and Tat against AIDS. , 1999, Vaccine.
[81] J. Heeney,et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.
[82] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[83] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.
[84] P. Secchiero,et al. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. , 1999, Journal of immunology.
[85] J. Metcalf,et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART , 1999, The Lancet.
[86] Irene Bosch,et al. Tat Protein Induces Human Immunodeficiency Virus Type 1 (HIV-1) Coreceptors and Promotes Infection with both Macrophage-Tropic and T-Lymphotropic HIV-1 Strains , 1998, Journal of Virology.
[87] W. Blattner,et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. , 1998, Journal of human virology.
[88] V Chams,et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[89] K. Yamada,et al. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. , 1997, Journal of immunology.
[90] Luigi Buonaguro,et al. HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.
[91] D. Burton. A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[92] G. Nolan,et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. , 1997, Journal of immunology.
[93] A. Pardee,et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[94] K. Okuda,et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes , 1997, Journal of virology.
[95] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[96] F. Miedema,et al. HIV-1 REV and TAT specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to aids , 1997 .
[97] C. Van Lint,et al. Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway , 1997, Science.
[98] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .
[99] S. Fawell,et al. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens , 1996, Molecular biotechnology.
[100] S. Capitani,et al. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. , 1996, Journal of immunology.
[101] R. Jenkins,et al. Incentives and disincentives to participate in prophylactic HIV vaccine research. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[102] B. Ensoli,et al. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. , 1995, The Journal of clinical investigation.
[103] T. Curiel,et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes , 1995, Nature Medicine.
[104] M. Raffeld,et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.
[105] F. Buonaguro,et al. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure , 1994, Journal of virology.
[106] C. Ambrosino,et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein , 1994, The Journal of experimental medicine.
[107] E. Miller,et al. Confounding factors in the measurement of depression in HIV. , 1994, Journal of personality assessment.
[108] R. Gallo,et al. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[109] K. Manchester,et al. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[110] J. Giorgi,et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. , 1993, Journal of immunology.
[111] P. Wingfield,et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.
[112] L. Buonaguro,et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. , 1992, Journal of immunology.
[113] L. Buonaguro,et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines , 1992, Journal of virology.
[114] R. Puri,et al. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. , 1992, Cancer research.
[115] R. Gallo,et al. Cytokines and Growth Factors in the Pathogenesis of AIDS‐Associated Kaposi's Sarcoma , 1992, Immunological reviews.
[116] B. Aggarwal,et al. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. , 1990, The Journal of biological chemistry.
[117] S. Salahuddin,et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.
[118] J. Bell,et al. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. , 1990, Journal of immunology.
[119] C. Debouck,et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 , 1990, Journal of medical virology.
[120] Carl O. Pabo,et al. Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.
[121] C. Debouck,et al. Natural antibodies to HIV‐tat epitopes and expression of HIV‐1 genes in vivo , 1988, Journal of medical virology.
[122] B. Cullen,et al. Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[123] J. Sodroski,et al. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication , 1986, Cell.
[124] S. Arya,et al. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). , 1985, Science.
[125] Mark L. Pearson,et al. Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.
[126] Amiram Gafni,et al. Highly Active Antiretroviral Therapy , 2012, PharmacoEconomics.
[127] M. Magnani,et al. HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection , 2009 .
[128] L. Kostrikis,et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. , 2002, Nature Reviews Immunology.
[129] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.
[130] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. , 1996, The Journal of infectious diseases.
[131] B. Cullen. Regulation of HIV gene expression. , 1995, AIDS.
[132] C. Burtis. Tietz textbook of Clinical Chemistry , 1994 .
[133] C. Debouck,et al. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. , 1991, Journal of acquired immune deficiency syndromes.
[134] K. Mullis,et al. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. , 1987, Methods in enzymology.
[135] M. Gonda,et al. The trans-activator gene of HTLV-III is essential for virus replication , 1986, Nature.
[136] C. Spielberger,et al. Manual for the State-Trait Anxiety Inventory , 1970 .
[137] A. Geretti,et al. Uva-dare (digital Academic Repository) Human Immunodeficiency Virus Type 1 Rev-and Tat-specific Cytotoxic T Lymphocyte Frequencies Inversely Correlate with Rapid Progression to Aids , 2022 .